HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy
Open accessThe DOI matches its Crossref record; 95 of the 99 references it cites were found in a registry or an index; 48 of the 101 sources its claims cite were checked for support.
Abstract
Hepatocellular carcinoma (HCC) is a major cause of cancer mortality worldwide and available therapies, including immunotherapies, are ineffective for many patients. HCC is characterized by intratumoral hypoxia, and increased expression of hypoxia-inducible factor 1α (HIF-1α) in diagnostic biopsies is associated with patient mortality...
Overview
CoChat Summary
## TL;DR
This paper identifies 32-134D, a low-molecular-weight HIF inhibitor, as a suppressor of HCC growth that blocks both HIF-1 and HIF-2 activity in human and mouse HCC models. In immunocompetent Hepa1-6 mice, adding 32-134D to anti-PD1 increased complete tumor eradication from 25% to 67%.
## Key findings
- In hypoxic Hep3B cells, 32-134D significantly inhibited HIF-dependent reporter activity with an IC50 of 2.9 μM, and 252 analogs yielded 27 compounds with HIF-transcriptional IC50 values below 3.3 μM.
- In Hep3B xenografts, daily intraperitoneal 32-134D caused partial growth inhibition at 20 mg/kg and maximal inhibition at 40 and 80 mg/kg; treated tumors showed decreased mass and reduced CD31-positive blood vessel area.
- RNA-seq in hypoxic Hep3B cells showed that 3,326 of 3,849 hypoxia-induced genes (86%) were inhibited by 32-134D; overall, 4,689 genes were inhibited, and a 15-gene HIF signature was associated with survival of 364 HCC patients (82 months vs 42 months, P = 0.006).
- In syngeneic Hepa1-6 tumors, 32-134D increased complete responses to anti-PD1 from 25% (3/12) to 67% (8/12), while 32-134D alone eradicated tumors in 4 of 12 mice.
- 32-134D shifted the tumor immune microenvironment toward antitumor immunity: it increased CD8+IFN-γ+ effector T cells, activated CD8+ T cells, and activated NK cells, and decreased TAMs and M-MDSCs; the effector T-cell:TAM ratio increased 3-fold.
- Safety signals were limited in mice: no changes were seen in appearance, behavior, body weight, hemoglobin, hematocrit, serum EPO, or histology of brain, colon, heart, kidney, liver, lungs, or small intestine after 14 days at 40 or 80 mg/kg/day.
## Methods
- The study combined an NCI-60 virtual screen, chemical synthesis of lead analogs, in vitro reporter assays and RT-qPCR, mouse xenograft and syngeneic HCC models, flow cytometry, ELISA, immunohistochemistry, and RNA-seq.
- Human Hep3B and mouse Hepa1-6 HCC cells were used; Hep3B xenografts were grown in nude mice, and Hepa1-6 tumors were grown in C57L mice, with treatment by daily intraperitoneal 32-134D, anti-PD1, or both.
- Main analyses included FLuc/RLuc reporter assays under 1% O2, RT-qPCR/RNA-seq with differential expression thresholds of FDR < 0.05 and fold change > 1.5, tumor immune-cell profiling by flow cytometry, and pharmacokinetics by LC-MS/MS.
## Limitations
- The paper states that further studies are required to determine whether steady-state plasma levels of 32-134D are achieved with daily administration.
- The work is preclinical and limited to cell lines and mouse models; clinical efficacy in humans is not tested in the paper.
- Evident from the text: some mechanistic claims about stromal versus tumor-cell effects are inferential, because differential effects in tumors versus cultured Hepa1-6 cells suggest but do not directly prove the responsible cell types.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
24 Valid · 3 Not valid · 18 Not checked · 97 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Many patients may fail to respond to immune checkpoint inhibitors because of the coexistence of other mechanisms of immune evasion, such as the production of adenosine, which binds to its cognate receptor on T cells to trigger apoptosis (13), or the absence of sufficient T and NK cells in the tumor to serve as targets for anti-PD1 (14).”
§ HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy > Introduction
What the sources say
- Disputedcites [13] Huang, 1997, Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion, Blood sourceExperimental — accuracy not yet measured
The citation is attached to the claim that adenosine binds a T-cell receptor to trigger apoptosis, not to the separate claim about insufficient T and NK cells. The Abstract (page unavailable) reports A2a receptor-mediated inhibition of T-cell activation and proliferation at low extracellular adenosine concentrations, but explicitly says direct lymphotoxicity was not observed. It therefore does not support receptor-triggered apoptosis as the mechanism. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [14] matched to “Immune Escape Mechanisms as a Guide for Cancer Immunotherapy” (2015) sourceExperimental — accuracy not yet measured
The Tailoring cancer immunotherapy section (page unavailable) says tumors with weak lymphocyte infiltration may need treatment that brings tumor-specific T cells into the tumor before anti-PD-1 therapy can be effective. It does not identify a shortage of NK cells as a reason anti-PD-1 lacks targets. Adenosine production is attached to a different citation in the citing sentence, so it is not assessed here. (LLM, conf=0.85)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Hypoxia-inducible factors (HIFs) play critical roles in cancer progression by activating the transcription of a large battery of genes encoding proteins that play key roles in angiogenesis, glucose metabolism, invasion/metastasis, stem cell specification, protumoral inflammatory responses, and tumor immune evasion (18, 23–27).”
§ HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy > Introduction
What the sources say
- Not checked — no full text of the sourcecites [18] matched to “Hypoxia-Inducible Factors: Master Regulators of Cancer Progression” (2016) source
- Supportedcites [23] matched to “HIFs, angiogenesis, and metabolism: Elusive enemies in breast cancer” (2020) source
The Introduction describes HIFs as important to cancer progression, and ‘HIF activity in breast cancer’ states that HIF induces transcription of target genes. The review also discusses HIF-linked angiogenesis, glucose metabolism, invasion and metastasis, breast cancer stem-cell traits, proinflammatory factors, and an immunosuppressive tumor microenvironment. The claim is a fair synthesis of those passages, though the review focuses on breast cancer; page numbers are not available for most passages in our copy. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [24] matched to “Metabolic adaptation of cancer and immune cells mediated by hypoxia-inducible factors” (2018) source
- Not checked — no full text of the sourcecites [25] Semenza, 2021, Intratumoral hypoxia and mechanisms of immune evasion mediated by hypoxia-inducible factors, Physiology (Bethesda) source
- Partly supportedcites [26] matched to “Hypoxia-inducible factors: a central link between inflammation and cancer” (2016) sourceExperimental — accuracy not yet measured
The Introduction describes HIFs as transcription factors and critical drivers of cancer that regulate metabolism, angiogenesis, and invasion/metastasis. The Conclusion and “Hypoxic regulation of tumor immune cell function” also connect HIF signaling to protumor inflammation and suppression of antitumor immunity. Our copy does not support the specific addition of stem cell specification to this list. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [27] Xiang, 2019, Hypoxia-inducible factors promote breast cancer stem cell specification and maintenance in response to hypoxia or cytotoxic chemotherapy, Adv Cancer Res source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Intratumoral hypoxia is a major driving force for cancer progression (15–19).”
§ HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy > Introduction
What the sources say
- Partly supportedcites [15] matched to “Hypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer” (2021) sourceExperimental — accuracy not yet measured
Section 2 says intratumoral hypoxia in hepatocellular carcinoma induces metabolic changes that promote drug resistance. Section 3.1 links conditions in the tumor microenvironment to faster tumor progression. These passages support a role for hypoxia in progression, but do not establish that it is a major driving force for cancer progression generally. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [16] matched to “Hypoxia — a key regulatory factor in tumour growth” (2002) source
- Supportedcites [17] matched to “Antihypoxic oxygenation agents with respiratory hyperoxia to improve cancer immunotherapy” (2020) source
The Introduction says hypoxia-induced HIF-1α helps tumor cells adapt and thrive and strengthens immunosuppressive signaling. The section “Targeting immunosuppressive hypoxia/HIF-1α axis” also describes the protumor effects of hypoxia, supporting the broad claim that intratumoral hypoxia drives cancer progression. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [18] matched to “Hypoxia-Inducible Factors: Master Regulators of Cancer Progression” (2016) source
- Not checked — no full text of the sourcecites [19] matched to “Detection and Characterization of Tumor Hypoxia Using pO 2 Histography” (2007) source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In mouse models, hypoxic zones within tumors were shown to lack T cells (37, 38).”
§ HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy > Introduction
What the sources say
- Partly supportedcites [37] Hatfield, 2015, Immunological mechanisms of the antitumor effects of supplemental oxygenation, Sci Transl Med sourceExperimental — accuracy not yet measured
The Results section reports markedly fewer CD4 and CD8 T cells in hypoxic tumor areas than in neighboring normoxic areas in mouse models. It does not say those areas lack T cells entirely. No page number is provided in our copy. (LLM, conf=0.88)
- Supportedcites [38] matched to “Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy” (2018) source
In the section “Hypoxic zones within prostate tumors lack T cells” and its continuation (page not specified in the excerpt), the authors report that T cells were largely excluded from hypoxic zones in two mouse models of prostate cancer. This supports the citing sentence’s claim about mouse models. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“B7H4 and TIM3 mRNA, which are encoded by the Vtcn1 and Havcr2 genes, respectively, and like PDL1, encode immune checkpoint receptors that are HIF regulated (51, 52) and associated with patient mortality in HCC (53), showed hypoxia-induced expression in vehicle-treated but not in 32-134D–treated cells (P < 0.05; Figure 3B).”
§ HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy > Results > Effects of 32-134D on Hepa1-6 mouse HCC cells and tumors.
What the sources say
- Not checked — no full text of the sourcecites [51] matched to “Cancer cell-associated cytoplasmic B7–H4 is induced by hypoxia through hypoxia-inducible factor-1α and promotes cancer cell proliferation” (2015) source
- Partly supportedcites [52] matched to “The HIF-1/glial TIM-3 axis controls inflammation-associated brain damage under hypoxia” (2015) sourceExperimental — accuracy not yet measured
The Results section, “TIM-3 is elevated in a HIF-1-dependent manner under hypoxia” (page unavailable), reports increased TIM-3 transcripts under hypoxia and HIF-1-dependent regulation in glial cells. It does not report B7H4 expression or the vehicle-versus-32-134D result in Hepa1-6 cells. In the citing sentence, the citations accompany the HIF-regulation background statement; Figure 3B accompanies the cell-treatment result. (LLM, conf=0.88)
- Supportedcites [53] matched to “Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma” (2018) source
Citation 53 supports the sentence’s claim that B7-H4 and TIM-3 are associated with mortality in HCC patients. The Abstract reports that both were independently associated with worse prognosis, and the Discussion links each to worse overall survival. The hypoxia and 32-134D result is attributed to the citing paper’s Figure 3B, not to this source. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
85 more claims · 4 with their cited sources checked
Create a free account to see all 142 claims and every source verdict.
- It may state two separate claims as one. 33
- Probably not a substantial claim. 26
- Borderline: one of the tests for a substantial claim is unclear. 1
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Targeting HIF‐1α reverses immune dysfunction and overcomes resistance to PD‐L1 blockade.”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [114]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Thus, HIF-1/2α inhibition in mouse models of cancer promotes the efficacy of anti-PD1 therapy and increases infiltration of cytotoxic immune effector cells [84–86].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [86]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Treatment with this compound reduced HIF-1α and, to a lesser extent, HIF-2α protein levels without altering HIF1A or EPAS1 mRNA expression.”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [334]
The cited source says what the claim attributes to it.
In the citing paper
“the small molecule 32-134D was identified as suppressing HIF-α accumulation in hepatocellular carcinoma cell lines.”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [334]
The cited source says what the claim attributes to it.
In the citing paper
“Proteasome inhibition abrogated this effect, suggesting enhanced proteasomal turnover of HIF-α subunits, although direct measurements of protein half-life were not performed [334].”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [334]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy > Discussion
“In particular, the efficacy of many immunotherapies is dependent on the presence of intratumoral CD8+ T cells, which are significantly increased by treatment with 32-124D.”
§ HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy > Abstract
“Here we report the development of 32-134D, a low-molecular-weight compound that effectively inhibits gene expression mediated by HIF-1 and HIF-2 in HCC cells, and blocks human and mouse HCC tumor growth.”
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“We previously screened a library of 3,140 drugs and identified acriflavine as a drug that inhibits HIF activity by disrupting subunit dimerization, and blocks HCC tumor growth and vascularization in mouse models (41).”
Cited work 10.1073/pnas.0909353106 · retracted 2023-04-26 · notice 10.1073/pnas.2305537120 · this paper published 2022-05-02
Citations
Cites
1 retracted
RETRACTED: Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization
Lee, K., Zhang, H., Qian, D. Z., Rey, S., Liu, J. O., & Semenza, G. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909353106 · Cited by 451 · cited 1×
“We previously screened a library of 3,140 drugs and identified acriflavine as a drug that inhibits HIF activity by disrupting subunit dimerization, and blocks HCC tumor growth and vascularization in mouse models (41).”
BackgroundSelf-citationRetractedModerated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219 · cited 1×
“quantified with featureCounts (94), and differential gene expres-”
MethodSorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470 · cited 1×
“5-month improvement in progression-free survival as compared with sorafenib, although more than half of patients receiving the combination therapy suffered grade 3 or 4 adverse events (11).”
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055 · cited 1×
“Nivolumab, an anti-PD1 antibody, was granted FDA approval for HCC based on phase II trial data, but a phase III trial versus sorafenib as first-line therapy did not meet its primary endpoint with respect to overall survival (OS), and a phase III trial of pembrolizumab, another anti-PD1 antibody, also failed versus pla…”
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 1×
“Cells were treated with compounds the following day multiple immune checkpoint blockade therapies is a strategy to increase responders, but among HCC patients, only 33% responded to treatment with anti-CTLA4 and anti-PD1 antibodies (12), which is a regimen that places patients at increased risk for life-threatening au…”
BackgroundEl-Serag, H. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1001683 · Cited by 3,529
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., Chen, Q., Gindin, M., Gubin, M. M., van der Windt, G. J. W., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.016 · Cited by 3,331
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088 · cited 1×
“Immune checkpoint blockade therapy has had a major impact on cancer by unleashing antitumor immunity that leads to durable tumor regression (87).”
BackgroundFunctional Polarization of Tumour-Associated Macrophages by Tumour-Derived Lactic Acid
Colegio, O. R., Chu, N.-Q., Szabo, A. L., Chu, T., Rhebergen, A. M., Jairam, V., Cyrus, N., Brokowski, C. E., Eisenbarth, S. C., Phillips, G. M., et al. (2014) · Nature · doi:10.1038/nature13490 · Cited by 3,046
Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis
Chang, C.-H., Curtis, J. D., Maggi, L. B., Faubert, B., Villarino, A. V., O’Sullivan, D., Huang, S. C.-C., van der Windt, G. J. W., Blagih, J., Qiu, J., et al. (2013) · Cell · doi:10.1016/j.cell.2013.05.016 · Cited by 2,204
Immunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057 · cited 1×
“It is likely that the poor response rate across all human cancers is due in part to the multiplicity of molecular mechanisms (90), many of them regulated by HIFs (25), by which cancer cells evade the immune system.”
BackgroundLDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells
Brand, A., Singer, K., Koehl, G. E., Kolitzus, M., Schoenhammer, G., Thiel, A., Matos, C., Bruss, C., Klobuch, S., Peter, K., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.08.011 · Cited by 2,039
Inhibitory effect of tumor cell-derived lactic acid on human T cells
Fischer, K., Hoffmann, P., Voelkl, S., Meidenbauer, N., Ammer, J., Edinger, M., Gottfried, E., Schwarz, S., Rothe, G., Hoves, S., et al. (2007) · Blood · doi:10.1182/blood-2006-07-035972 · Cited by 1,946
HIF transcription factors, inflammation, and immunity
Palazon, A., Goldrath, A. W., Nizet, V., & Johnson, R. S. (2014) · Immunity · doi:10.1016/j.immuni.2014.09.008 · Cited by 1,195
Hepatocellular carcinoma: a review
Balogh, J., Victor, D., Asham, E. H., Burroughs, S. G., Boktour, M., Saharia, A., Li, X., Ghobrial, M., & Monsour, H. (2016) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s61146 · Cited by 1,185
Corzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J.-I., Cheng, P., Cho, H.-I., Celis, E., Quiceno, D. G., Padhya, T., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100587 · Cited by 1,173
Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
Beatty, G. L., & Gladney, W. L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1860 · Cited by 1,078 · cited 1×
“Many patients may fail to respond to immune checkpoint inhibitors because of the coexistence of other mechanisms of immune evasion, such as the production of adenosine, which binds to its cognate receptor on T cells to trigger apoptosis (13), or the absence of sufficient T and NK cells in the tumor to serve as targets…”
BackgroundDefining normoxia, physoxia and hypoxia in tumours—implications for treatment response
McKeown, S. R. (2014) · The British Journal of Radiology · doi:10.1259/bjr.20130676 · Cited by 1,050 · cited 1×
“In liver metastases of colorectal cancer, the median PO2 was 6 mmHg as compared with 30 mmHg in normal liver tissue (20).”
BackgroundNeoadjuvant checkpoint blockade for cancer immunotherapy
Topalian, S. L., Taube, J. M., & Pardoll, D. M. (2020) · Science · doi:10.1126/science.aax0182 · Cited by 1,001 · cited 1×
“However, response rates of only 15% to 30% have been observed in most cancer types (88).”
BackgroundHypoxia-Inducible Factors: Master Regulators of Cancer Progression
Schito, L., & Semenza, G. L. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.10.016 · Cited by 962
Self-citationReinhold, W. C., Sunshine, M., Liu, H., Varma, S., Kohn, K. W., Morris, J., Doroshow, J., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1370 · Cited by 887 · cited 1×
“The NCI CellMiner database contains expression data for over 25,000 mRNAs in 60 human cancer cell lines that have been exposed to more than 20,000 chemical compounds (49).”
BackgroundThe effects of extracellular pH on immune function
Lardner, A. (2001) · Journal of Leukocyte Biology · doi:10.1189/jlb.69.4.522 · Cited by 864
Detection and Characterization of Tumor Hypoxia Using pO 2 Histography
Vaupel, P., Höckel, M., & Mayer, A. (2007) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1628 · Cited by 728 · cited 1×
“The data indicate that 32-134D and 33-063 inhibit transcription mediated by both less than 10 mmHg (19).”
BackgroundBelzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease
Jonasch, E., Donskov, F., Iliopoulos, O., Rathmell, W. K., Narayan, V. K., Maughan, B. L., Oudard, S., Else, T., Maranchie, J. K., Welsh, S. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103425 · Cited by 714 · cited 1×
“1172/JCI156774 2 of RCC in patients with von Hippel-Lindau syndrome (47, 48).”
BackgroundDoedens, A. L., Stockmann, C., Rubinstein, M. P., Liao, D., Zhang, N., DeNardo, D. G., Coussens, L. M., Karin, M., Goldrath, A. W., & Johnson, R. S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1439 · Cited by 652
Calcinotto, A., Filipazzi, P., Grioni, M., Iero, M., De Milito, A., Ricupito, A., Cova, A., Canese, R., Jachetti, E., Rossetti, M., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1272 · Cited by 640
Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
Zhang, H., Qian, D. Z., Tan, Y. S., Lee, K., Gao, P., Ren, Y. R., Rey, S., Hammers, H., Chang, D., Pili, R., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809763105 · Cited by 624
Self-citationTopalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Sosman, J. A., Atkins, M. B., Leming, P. D., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.2187 · Cited by 619
Immunological mechanisms of the antitumor effects of supplemental oxygenation
Hatfield, S. M., Kjaergaard, J., Lukashev, D., Schreiber, T. H., Belikoff, B., Abbott, R., Sethumadhavan, S., Philbrook, P., Ko, K., Cannici, R., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1260 · Cited by 600 · cited 2×
“The critical role of intratumoral hypoxia as the stimulus for immunosuppression was also demonstrated by exposing tumor-bearing mice to an ambient O2 concentration of 60%, which was sufficient to alter the tumor microenvironment from immunosuppression to antitumor immunity (37).”
BackgroundNeutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy
Pilon-Thomas, S., Kodumudi, K. N., El-Kenawi, A. E., Russell, S., Weber, A. M., Luddy, K., Damaghi, M., Wojtkowiak, J. W., Mulé, J. J., Ibrahim-Hashim, A., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1743 · Cited by 593
Huang, S., Apasov, S., Koshiba, M., & Sitkovsky, M. (1997) · Blood · doi:10.1182/blood.v90.4.1600 · Cited by 531 · cited 2×
“The connection between immune evasion and intratumoral hypoxia was established by groundbreaking studies demonstrating that hypoxia induces increased expression of CD73, the enzyme that mediates production of extracellular adenosine, which binds to adenosine 2A receptors on T lymphocytes and natural killer (NK) cells,…”
BackgroundAn HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression
Palazon, A., Tyrakis, P. A., Macias, D., Veliça, P., Rundqvist, H., Fitzpatrick, S., Vojnovic, N., Phan, A. T., Loman, N., Hedenfalk, I., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.003 · Cited by 521 · cited 1×
“In contrast to the studies described above, which implicated HIF-dependent adenosine production by cancer cells as a non-cell-autonomous mechanism of immunosuppression, other studies supported the hypothesis that HIF activity was required in a cell-autonomous manner for the antitumor activity of CD8+ T cells (39, 40).”
ResultMenyhárt, O., Nagy, Á., & Győrffy, B. (2018) · Royal Society Open Science · doi:10.1098/rsos.181006 · Cited by 507 · cited 1×
“Kaplan-Meier survival analysis (96) was performed using the log-rank”
MethodChiu, D. K.-C., Tse, A. P.-W., Xu, I. M.-J., Di Cui, J., Lai, R. K.-H., Li, L. L., Koh, H.-Y., Tsang, F. H.-C., Wei, L. L., Wong, C.-M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00530-7 · Cited by 448 · cited 4×
“Treatment with 32-134D led to decreased expression of the Th2 cytokines IL-4 and IL-13, which together with CXCL1, mediate recruitment or maintenance of immunosuppressive MDSCs and TAMs (72, 73).”
BackgroundInfluentialJayaprakash, P., Ai, M., Liu, A., Budhani, P., Bartkowiak, T., Sheng, J., Ager, C., Nicholas, C., Jaiswal, A. R., Sun, Y., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96268 · Cited by 399 · cited 1×
“In mouse models, hypoxic zones within tumors were shown to lack T cells (37, 38).”
BackgroundCourtney, K. D., Infante, J. R., Lam, E. T., Figlin, R. A., Rini, B. I., Brugarolas, J., Zojwalla, N. J., Lowe, A. M., Wang, K., Wallace, E. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.2627 · Cited by 393 · cited 1×
“A phase I trial of PT2385 reported grade 3 anemia in 10% of patients (46).”
BackgroundHIFs, angiogenesis, and metabolism: Elusive enemies in breast cancer
de Heer, E. C., Jalving, M., & Harris, A. L. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137552 · Cited by 372
A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma
Wallace, E. M., Rizzi, J. P., Han, G., Wehn, P. M., Cao, Z., Du, X., Cheng, T., Czerwinski, R. M., Dixon, D. D., Goggin, B. S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0473 · Cited by 336 · cited 2×
“For comparison, we tested the effect of PT2385, which inhibited EPO, NDRG1, ANGPTL4, and VEGFA expression but had no effect on CA9, which is consistent with its HIF-2–selective mechanism of action (44).”
MethodResultHypoxia‐inducible factors in regulation of immune responses in tumour microenvironment
Kumar, V., & Gabrilovich, D. I. (2014) · Immunology · doi:10.1111/imm.12380 · Cited by 329
Ni, J., Wang, X., Stojanovic, A., Zhang, Q., Wincher, M., Bühler, L., Arnold, A., Correia, M. P., Winkler, M., Koch, P.-S., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.05.001 · Cited by 324
Hypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer
Bao, M. H.-R., & Wong, C. C.-L. (2021) · Cells · doi:10.3390/cells10071715 · Cited by 316
Choueiri, T. K., Bauer, T. M., Papadopoulos, K. P., Plimack, E. R., Merchan, J. R., McDermott, D. F., Michaelson, M. D., Appleman, L. J., Thamake, S., Perini, R. F., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01324-7 · Cited by 305
Samanta, D., Park, Y., Ni, X., Li, H., Zahnow, C. A., Gabrielson, E., Pan, F., & Semenza, G. L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718197115 · Cited by 302 · cited 3×
“Acriflavine treatment of tumor-bearing mice was recently reported to increase intratumoral CD8+ T cells and NK cells (42, 43).”
BackgroundSelf-citationPharmacologic Targeting of Hypoxia-Inducible Factors
Semenza, G. L. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021637 · Cited by 288 · cited 3×
“HIFs consist of an O2-regulated HIF-1α, HIF-2α, or HIF-3α subunit and a constitutively expressed HIF-1β subunit (28).”
BackgroundSelf-citationComparison of hepatocellular carcinoma in Eastern versus Western populations
Choo, S. P., Tan, W. L., Goh, B. K. P., Tai, W. M., & Zhu, A. X. (2016) · Cancer · doi:10.1002/cncr.30237 · Cited by 264
Chiu, D. K., Xu, I. M., Lai, R. K., Tse, A. P., Wei, L. L., Koh, H., Li, L. L., Lee, D., Lo, R. C., Wong, C., et al. (2016) · Hepatology · doi:10.1002/hep.28655 · Cited by 241
Ma, H.-Y., Yamamoto, G., Xu, J., Liu, X., Karin, D., Kim, J. Y., Alexandrov, L. B., Koyama, Y., Nishio, T., Benner, C., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.12.016 · Cited by 216
Sitkovsky, M. V., Hatfield, S., Abbott, R., Belikoff, B., Lukashev, D., & Ohta, A. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0075 · Cited by 215 · cited 2×
“The connection between immune evasion and intratumoral hypoxia was established by groundbreaking studies demonstrating that hypoxia induces increased expression of CD73, the enzyme that mediates production of extracellular adenosine, which binds to adenosine 2A receptors on T lymphocytes and natural killer (NK) cells,…”
BackgroundHypoxia-inducible factors: a central link between inflammation and cancer
Triner, D., & Shah, Y. M. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84430 · Cited by 199
(2002) · PubMed · Cited by 193
Metabolic adaptation of cancer and immune cells mediated by hypoxia-inducible factors
Samanta, D., & Semenza, G. L. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.07.002 · Cited by 190
Self-citationHypoxia-inducible factors and innate immunity in liver cancer
Yuen, V. W.-H., & Wong, C. C.-L. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137553 · Cited by 183 · cited 1×
“05; Figure 5, D and E), which are 2 immune cell populations that are critical mediators of immunosuppression in HCC (55).”
BackgroundThe Role of Tumor Microenvironment in Cancer Immunotherapy
Frankel, T., Lanfranca, M. P., & Zou, W. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-67577-0_4 · Cited by 173 · cited 1×
“Finally, the parallel increase in NK cells enables killing of cancer cells that have downregulated the expression of class I MHC proteins to evade killing by T cells (91, 92).”
BackgroundNakagawa, Y., Negishi, Y., Shimizu, M., Takahashi, M., Ichikawa, M., & Takahashi, H. (2015) · Immunology Letters · doi:10.1016/j.imlet.2015.07.003 · Cited by 149
Glioblastomas Induce T-Lymphocyte Death by Two Distinct Pathways Involving Gangliosides and CD70
Chahlavi, A., Rayman, P., Richmond, A. L., Biswas, K., Zhang, R., Vogelbaum, M., Tannenbaum, C., Barnett, G., & Finke, J. H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4395 · Cited by 141 · cited 1×
“Treatment with 32-134D also decreased the expression of CD70, which has been implicated in immune evasion of cancer cells through induction of T cell exhaustion or apoptosis in glioblastoma (74, 75) and RCC (76).”
BackgroundThe HIF-1/glial TIM-3 axis controls inflammation-associated brain damage under hypoxia
Koh, H. S., Chang, C. Y., Jeon, S.-B., Yoon, H. J., Ahn, Y.-H., Kim, H.-S., Kim, I.-H., Jeon, S. H., Johnson, R. S., & Park, E. J. (2015) · Nature Communications · doi:10.1038/ncomms7340 · Cited by 141 · cited 1×
“B7H4 and TIM3 mRNA, which are encoded by the Vtcn1 and Havcr2 genes, respectively, and like PDL1, encode immune checkpoint receptors that are HIF regulated (51, 52) and associated with patient mortality in HCC (53), showed hypoxia-induced expression in vehicle-treated but not in 32-134D–treated cells (P < 0.”
BackgroundExpression of Liver Phenotypes in Cultured Mouse Hepatoma Cells 2
(1980) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/64.4.809 · Cited by 135 · cited 1×
“To test whether 32-134D inhibits HCC growth in an immunocompetent mouse model, we injected Hepa1-6 HCC cells into the flank of syngeneic C57L mice (54).”
MethodThe role of IL-11 in immunity and cancer
Xu, D. H., Zhu, Z., Wakefield, M. R., Xiao, H., Bai, Q., & Fang, Y. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.01.004 · Cited by 134
Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma
Shrestha, R., Prithviraj, P., Anaka, M., Bridle, K. R., Crawford, D. H. G., Dhungel, B., Steel, J. C., & Jayachandran, A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00269 · Cited by 132 · cited 2×
“However, in Hepa1-6 tumors, 32-134D inhibited the expression of the checkpoint ligands B7H4 and PDL1, and the checkpoint receptor TIM3, which are all associated with mortality in HCC (53).”
BackgroundWada, H., Nagano, H., Yamamoto, H., Yang, Y., Kondo, M., Ota, H., Nakamura, M., Yoshioka, S., Kato, H., Damdinsuren, B., et al. (2006) · Liver International · doi:10.1111/j.1478-3231.2006.01243.x · Cited by 130
Self-citationLequeux, A., Noman, M. Z., Xiao, M., Van Moer, K., Hasmim, M., Benoit, A., Bosseler, M., Viry, E., Arakelian, T., Berchem, G., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01846-x · Cited by 129 · cited 1×
“Acriflavine treatment of tumor-bearing mice was recently reported to increase intratumoral CD8+ T cells and NK cells (42, 43).”
BackgroundSethumadhavan, S., Silva, M., Philbrook, P., Nguyen, T., Hatfield, S. M., Ohta, A., & Sitkovsky, M. V. (2017) · PLOS ONE · doi:10.1371/journal.pone.0187314 · Cited by 119 · cited 1×
“Finally, the parallel increase in NK cells enables killing of cancer cells that have downregulated the expression of class I MHC proteins to evade killing by T cells (91, 92).”
BackgroundBustos, M., Beraza, N., Lasarte, J.-J., Baixeras, E., Alzuguren, P., Bordet, T., & Prieto, J. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00698-x · Cited by 97
Immune Escape for Renal Cell Carcinoma: CD70 Mediates Apoptosis in Lymphocytes
Diegmann, J., Junker, K., Loncarevic, I. F., Michel, S., Schimmel, B., & von Eagelinq, F. (2006) · Neoplasia · doi:10.1593/neo.06451 · Cited by 92 · cited 4×
“Immune checkpoint blockade with antibodies that target programmed death 1 (PD1) or PD1 ligand 1 (PDL1) has revolutionized the treatment of advanced melanoma, non–small cell lung cancer, and renal cell carcinoma (RCC) (7–9).”
BackgroundInfluentialAntihypoxic oxygenation agents with respiratory hyperoxia to improve cancer immunotherapy
Hatfield, S. M., & Sitkovsky, M. V. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137554 · Cited by 73 · cited 1×
“The connection between immune evasion and intratumoral hypoxia was established by groundbreaking studies demonstrating that hypoxia induces increased expression of CD73, the enzyme that mediates production of extracellular adenosine, which binds to adenosine 2A receptors on T lymphocytes and natural killer (NK) cells,…”
BackgroundHermanns, H. M., Radtke, S., Haan, C., Schmitz-Van de Leur, H., Tavernier, J., Heinrich, P. C., & Behrmann, I. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.12.6651 · Cited by 71
(2019) · Advances in Cancer Research · doi:10.1016/bs.acr.2018.11.001 · Cited by 71
Self-citationTargeting hypoxia at the forefront of anticancer immune responses
Noman, M. Z., & Chouaib, S. (2014) · OncoImmunology · doi:10.4161/21624011.2014.954463 · Cited by 70
Intratumoral hypoxia and mechanisms of immune evasion mediated by hypoxia-inducible factors
Semenza, G. L. (2021) · Physiology · doi:10.1152/physiol.00034.2020 · Cited by 64
Self-citationXiang, Z.-L., Zeng, Z.-C., Fan, J., Tang, Z.-Y., He, J., Zeng, H.-Y., & Chang, J. Y. (2012) · Molecular Biology Reports · doi:10.1007/s11033-011-0949-1 · Cited by 52 · cited 1×
“In multiple studies involving a range of treatment modalities, as well as a meta-analysis, HIF-1α immunohistochemistry of tumor biopsies has revealed increased expression in over 60% of HCC cases and a significant association with decreased disease-free and OS (29–33) as well as increased risk of recurrence after radi…”
BackgroundModified Hypoxia-Inducible Factor Expression in CD8+ T Cells Increases Antitumor Efficacy
Veliça, P., Cunha, P. P., Vojnovic, N., Foskolou, I. P., Bargiela, D., Gojkovic, M., Rundqvist, H., & Johnson, R. S. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0561 · Cited by 52 · cited 1×
“In contrast to the studies described above, which implicated HIF-dependent adenosine production by cancer cells as a non-cell-autonomous mechanism of immunosuppression, other studies supported the hypothesis that HIF activity was required in a cell-autonomous manner for the antitumor activity of CD8+ T cells (39, 40).”
ResultRegulation of T-cell functions by l-lactate
Dröge, W., Roth, S., Altmann, A., & Mihm, S. (1987) · Cellular Immunology · doi:10.1016/0008-8749(87)90223-1 · Cited by 49
BIRC2 Expression Impairs Anti-Cancer Immunity and Immunotherapy Efficacy
Samanta, D., Huang, T. Y.-T., Shah, R., Yang, Y., Pan, F., & Semenza, G. L. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108073 · Cited by 49
Self-citationCao, S., Yang, S., Wu, C., Wang, Y., Jiang, J., & Lu, Z. (2014) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2014.04.004 · Cited by 45
Jeon, Y.-K., Park, S.-G., Choi, I.-W., Lee, S.-W., Lee, S. M., & Choi, I. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.02.098 · Cited by 41 · cited 1×
“B7H4 and TIM3 mRNA, which are encoded by the Vtcn1 and Havcr2 genes, respectively, and like PDL1, encode immune checkpoint receptors that are HIF regulated (51, 52) and associated with patient mortality in HCC (53), showed hypoxia-induced expression in vehicle-treated but not in 32-134D–treated cells (P < 0.”
BackgroundSelf-citationRiedl, C. C., Brader, P., Zanzonico, P. B., Chun, Y. S., Woo, Y., Singh, P., Carlin, S., Wen, B., Ling, C. C., Hricak, H., et al. (2008) · Radiology · doi:10.1148/radiol.2482071421 · Cited by 41
Osman, N. A. A., Abd El-Rehim, D. M., & Kamal, I. M. (2015) · Tumor Biology · doi:10.1007/s13277-015-3068-0 · Cited by 37
Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?
Lai, E., Astara, G., Ziranu, P., Pretta, A., Migliari, M., Dubois, M., Donisi, C., Mariani, S., Liscia, N., Impera, V., et al. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103167 · Cited by 35 · cited 1×
“Nivolumab, an anti-PD1 antibody, was granted FDA approval for HCC based on phase II trial data, but a phase III trial versus sorafenib as first-line therapy did not meet its primary endpoint with respect to overall survival (OS), and a phase III trial of pembrolizumab, another anti-PD1 antibody, also failed versus pla…”
IL-22 Signaling in the Tumor Microenvironment
Jiang, R., & Sun, B. (2021) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-55617-4_5 · Cited by 35
Xu, W., Kwon, J.-H., Moon, Y. H., Kim, Y. B., Yu, Y. S., Lee, N., Choi, K. Y., Kim, Y. S., Park, Y. K., Kim, B. W., et al. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1713-4 · Cited by 29
Srivastava, S., Thakkar, B., Yeoh, K. G., Ho, K. Y., Teh, M., Soong, R., & Salto-Tellez, M. (2015) · Virchows Archiv · doi:10.1007/s00428-015-1745-4 · Cited by 22
Xiao, H., Tong, R., Cheng, S., Lv, Z., Ding, C., Du, C., Xie, H., Zhou, L., Wu, J., & Zheng, S. (2014) · BioMed Research International · doi:10.1155/2014/516518 · Cited by 20
(2020) · PubMed · Cited by 19
Downregulation of B7-H4 suppresses tumor progression of hepatocellular carcinoma
Dong, L., Xie, L., Li, M., Dai, H., Wang, X., Wang, P., Zhang, Q., Liu, W., Hu, X., & Zhao, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-51253-2 · Cited by 15 · cited 5×
“Analysis of mRNA expression in tumor tissue by RT-qPCR revealed that 32-134D treatment significantly decreased the expression of multiple mRNAs encoding angiogenic factors (ANGPTL4, EPO, PGF, and VEGFA) (P < 0.05; Figure 6A) and proteins mediating immunosuppression (B7H4/VTCN1, CD47, CD73, PDL1, SLC2A1/GLUT1, HAVCR2/T…”
BackgroundInfluentialAn Autocrine Role for CXCL1 in Progression of Hepatocellular Carcinoma
DAHLQUIST, K. J. V., VOTH, L. C., FEE, A. J., & STOECKMAN, A. K. (2020) · Anticancer Research · doi:10.21873/anticanres.14628 · Cited by 13 · cited 11×
“Dahlquist KJV, et al. An autocrine role for CXCL1 in progression of hepatocellular carcinoma.”
BackgroundInfluential(2017) · PubMed Central · Cited by 11
IL-11 drives postsurgical hepatocellular carcinoma recurrence
Lauko, A., Bayik, D., & Lathia, J. D. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.007 · Cited by 7
Chen, B.-B., Hsu, C.-Y., Yu, C.-W., Liang, P.-C., Hsu, C., Hsu, C.-H., Cheng, A.-L., & Ting-Fang Shih, T. (2017) · Radiology · doi:10.1148/radiol.2017174012 · Cited by 7 · cited 1×
“Examination of human HCC patients by dynamic contrast-enhanced magnetic resonance imaging revealed that high intratumoral blood flow was associated with increased OS (22), which is consistent with an association between intratumoral hypoxia and patient mortality.”
Background
Cited by
Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions
Chen, Z., Han, F., Du, Y., Shi, H., & Zhou, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01332-8 · Cited by 1,612
“For instance, 32–134D, a low-molecular-weight compound that inhibits HIF-1/2-mediated gene expression in HCC cells, combined with anti-PD-1 increased HCC eradication rates in mice (from 25 to 67%).(401) HIF-1α inhibitors, such as topotecan, bortezomib (PS-341) as well as HIF-2α inhibitors, such as PT2399, PT2385 and P…”
BackgroundHypoxia-inducible factors: cancer progression and clinical translation
Wicks, E. E., & Semenza, G. L. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159839 · Cited by 580
“In immunocompetent mice bearing Hepa1-6 mouse HCC tumors, combined treatment with 32-134D and anti–PD-1 antibody resulted in tumor eradication in 67% of the mice compared with 25% of the mice treated with anti–PD-1 alone (177).”
BackgroundInfluentialSelf-citationPD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
Li, Q., Han, J., Yang, Y., & Chen, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1070961 · Cited by 246
Self-citationTargeting hypoxia-inducible factors: therapeutic opportunities and challenges
Yuan, X., Ruan, W., Bobrow, B., Carmeliet, P., & Eltzschig, H. K. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00848-6 · Cited by 245
“Thus, based on its similarity in gene target induction to acriflavine, 32-134D was recently identified as a nonspecific HIF inhibitor with a chemical structure unrelated to that of acriflavine 59 .”
InfluentialHypoxia signaling in cancer: Implications for therapeutic interventions
Zhuang, Y., Liu, K., He, Q., Gu, X., Jiang, C., & Wu, J. (2023) · MedComm · doi:10.1002/mco2.203 · Cited by 119
Metadata
- Authors
- Salman, S., Meyers, D. J., Wicks, E. E., Lee, S. N., Datan, E., Thomas, A. M., Anders, N. M., Hwang, Y., Lyu, Y., Yang, Y., Jackson, W., Dordai, D., Rudek, M. A., & Semenza, G. L.
- Affiliations
- Sidney Kimmel Cancer Center (US)
- Johns Hopkins University (US)
- Corresponding author
- Semenza, Gregg L.
- Venue
- Journal of Clinical Investigation
- Published
- 2022-05-02
- Volume
- 132
- Issue
- 9
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC9057582
- OpenAlex
- W4225257247
- Cited by
- 111
- References
- 99
- Citations by year
- 2026: 20 · 2025: 34 · 2024: 18 · 2023: 29 · 2022: 10
- FWCI
- 9.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Investigation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- American Cancer Society (RP-16-239-06-COUN)
- Armstrong Family Foundation (n/a)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- hepatocellular carcinoma, HIF-1α inhibition, HIF-2α inhibition, anti-PD-1 therapy, combination immunotherapy, tumor hypoxia, tumor immune microenvironment, tumor-associated macrophages, myeloid-derived suppressor cells, CD8+ T cells, natural killer cells, angiogenesis, glycolytic metabolism, immune evasion, antitumor immunity
- MeSH terms
- Animals, Hypoxia, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Neovascularization, Pathologic, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.